150 related articles for article (PubMed ID: 33317419)
1. Prognostic effect of RUNX1 mutations in myelodysplastic syndromes: a meta-analysis.
He W; Zhao C; Hu H
Hematology; 2020 Dec; 25(1):494-501. PubMed ID: 33317419
[TBL] [Abstract][Full Text] [Related]
2. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of
Liang S; Zhou X; Pan H; Yang Y; Shi L; Wang L
Hematology; 2019 Dec; 24(1):613-622. PubMed ID: 31482762
[No Abstract] [Full Text] [Related]
4. Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.
Hu C; Wang X
Leuk Lymphoma; 2022 Oct; 63(10):2336-2351. PubMed ID: 35543621
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.
Zheng X; Zhan Z; Naren D; Li J; Yan T; Gong Y
PLoS One; 2017; 12(9):e0185053. PubMed ID: 28953917
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
7. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF
Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of
Li B; Zou D; Yang S; Ouyang G; Mu Q
J Int Med Res; 2020 Mar; 48(3):300060519891013. PubMed ID: 31826693
[TBL] [Abstract][Full Text] [Related]
9. RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome.
Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
Leuk Lymphoma; 2019 May; 60(5):1334-1336. PubMed ID: 30997874
[No Abstract] [Full Text] [Related]
10. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
[TBL] [Abstract][Full Text] [Related]
11. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis.
Zhang A; Wang S; Ren Q; Wang Y; Jiang Z
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e183-e194. PubMed ID: 36471477
[TBL] [Abstract][Full Text] [Related]
13. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
14. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.
Arbab Jafari P; Ayatollahi H; Sadeghi R; Sheikhi M; Asghari A
Hematology; 2018 Dec; 23(10):778-784. PubMed ID: 29757120
[TBL] [Abstract][Full Text] [Related]
16. SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
Falantes JF; Márquez-Malaver FJ; Carrillo E; Culebras MG; Morales R; Prats C; Vargas MT; Caballero T; Rodríguez-Arbolí E; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1059-e1066. PubMed ID: 36117041
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of monosomal karyotype in myelodysplastic syndrome: a meta-analysis.
Wu YC; Zhang XM; Zhu YD; Wu W
Hematology; 2019 Dec; 24(1):60-69. PubMed ID: 30129389
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of RUNX1 Gene Mutation in Patients with Myelodysplastic Syndrome].
Cai XH; Chen MY; Chao HY; Jiang NK; Lu XZ; Han WM; Qin W; Jia ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):202-208. PubMed ID: 32027277
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
20. Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.
Tefferi A; Gangat N; Mudireddy M; Lasho TL; Finke C; Begna KH; Elliott MA; Al-Kali A; Litzow MR; Hook CC; Wolanskyj AP; Hogan WJ; Patnaik MM; Pardanani A; Zblewski DL; He R; Viswanatha D; Hanson CA; Ketterling RP; Tang JL; Chou WC; Lin CC; Tsai CH; Tien HF; Hou HA
Mayo Clin Proc; 2018 Oct; 93(10):1363-1374. PubMed ID: 29866419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]